THE HOUND — Tuesday, September 8, 2026
Beaufort tried to fetch the morning papers. Mistral’s €3 billion funding round needed a second trip.
He came back with Amazon’s next chip deal, an acquisition Anthropic reportedly passed on, and nine billion DNA predictions. The crossword will have to wait.
THE FRONT PAGE
Mistral’s €3 billion bet on independence
Mistral has raised €3 billion in a Series D at a post-money valuation above €21 billion. The company calls it the largest equity fundraising round completed by a European technology business.
Samsung Electronics led, with PSG Equity and the EQT-managed Scaleup Europe Fund co-leading. That is €3 billion raised by the whole investor group, not a €3 billion check from Samsung alone.
Mistral’s pitch is control: open-weight models, infrastructure and products that let customers decide where their data lives and how their AI runs. The money is intended to accelerate research, products and infrastructure.
For customers, the test is practical. Can Mistral offer enough capability, reliability and control to justify choosing it over the largest labs? A bigger balance sheet gives it more room to try.
Amazon gets chips and a stake in the outcome
Qualcomm announced a multi-generation collaboration with Amazon on AI data-center infrastructure. The financial terms make this more than a supplier announcement.
According to Qualcomm’s filing, Amazon received a warrant to acquire up to 25 million shares at $161.26 each. Multiplying those figures gives about $4.03 billion at the exercise price. That is not the warrant’s fair value or a cash payment to Amazon; the agreement also permits cashless exercise.
The warrant expires in September 2036. Vesting depends on commercial agreements, binding orders and actual purchases, with the payment threshold reaching $60 billion. An initial 3.75 million shares vested on issuance based on purchase commitments.
The distinction matters: $60 billion is not booked revenue or a guaranteed order. Amazon has an incentive to help the relationship grow; Qualcomm still has to deliver the products.
Anthropic reportedly passes on Decart
Bloomberg reports that Anthropic decided against buying Decart after conducting due diligence. Earlier talks valued a possible deal at about $6 billion. Both companies declined to comment, and one source said collaboration remains possible.
The reason for walking away has not been established in the reporting available here. There is no basis to turn a failed negotiation into a claim that something was wrong with Decart.
Samsung puts 2028 on the memory roadmap
Samsung and ASML are expanding their manufacturing partnership. Samsung plans to introduce High NA EUV lithography into high-volume DRAM production by 2028, which it describes as an industry first for memory.
In plain English, this is about using more precise chipmaking equipment to make smaller memory features. Samsung will also join work on larger, 12-inch photomasks, intended to improve production efficiency and reduce manufacturing constraints.
It is a manufacturing target, not a production line running today. The useful milestone will be whether the technology reaches reliable, economical mass production on that schedule.
Google changes EU Search, and disputes the trade-off
Google has rolled out European Search changes to comply with the Digital Markets Act, Reuters reports. Specialist comparison services receive more prominence, while some results lose features such as real-time prices.
Google argues that the changes make Search less useful and hurt direct traffic to businesses. That is the company’s position, not an independent verdict on the experience. The regulatory aim is to prevent Google from favoring its own services.
Watch who gets the clicks: comparison sites, the businesses themselves, or Google’s own services. That will tell us more than either side’s preferred description.
FROM THE PAPERS
A map of nine billion DNA changes
Google DeepMind released AlphaGenome Atlas, a roughly one-petabyte collection of predictions about nine billion possible single-letter changes in human DNA.
Instead of making researchers run every prediction themselves, the atlas lets them explore precomputed results. Its Variant Impact score helps prioritize changes that may affect how genes work, including in regions that do not encode proteins.
DeepMind says collaborators have used it in rare-disease research and studies of genetic associations. The promise is a shorter path from a vast list of possibilities to experiments worth doing.
The limits matter: these are predictions, not nine billion experimentally confirmed findings. AlphaGenome is not validated or approved for clinical use. The atlas is available for non-commercial use now, with commercial access through Google Cloud planned.
ON THE TRAIL
What Mistral releases next, and whether customers gain meaningful control without giving up too much performance.
Which product and purchasing milestones turn the Qualcomm–Amazon agreement into a larger operating business.
Whether Anthropic and Decart announce a partnership despite the reported acquisition walk-away.
Whether independent evidence supports Google’s claims about the EU Search changes.
That’s The Hound for today.
Beaufort will keep looking.
Everything worth knowing in tech, without the noise.